<DOC>
	<DOCNO>NCT00865267</DOCNO>
	<brief_summary>The purpose study determine duration application halobetasol propionate 0.05 % ointment use definitive study bioequivalence formulation ointment . Part A : To validate vasoconstrictor assay precision . Part B : To evaluate dose response vasoconstriction profile UltravateÂ® 0.05 % ointment different dose duration short period time ( 0.17 - 4 hr ) .</brief_summary>
	<brief_title>The Dose-response Study Topically Delivered Halobetasol Propionate Ointment Normal Skin Healthy Adult Subjects</brief_title>
	<detailed_description>Study Type : Interventional Study Design : A single blind , single-exposure study healthy adult male female subject . Official Title : A Single-blind , Single Exposure Study , Evaluate Vasoconstriction Activity Topically Delivered Halobetasol Propionate Ointment Normal Skin Healthy Adult Subjects : Dose Ranging Study Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Vasoconstrictor Response</detailed_description>
	<mesh_term>Halobetasol</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Subject understands study , willing participate , give write informed consent . Subject demonstrate adequate vasoconstriction screen topical corticosteroid Halobetasol propionate 0.05 % Ointment . Subject nonsmoking ( minimum 14 day ) , male female , age 18 65 year , inclusive . Subject within 20 % ideal body weight defined 1999 Metropolitan Life Insurance Company Height Weight Tables . Subject judge Investigator healthy basis prestudy medical history . Subjects childbearing potential agree use acceptable method birth control study participation ( e.g . abstinence , prescribed birth control method , double barrier method , Le . condom plus foam , condom plus diaphragm ) . Subject willing refrain excessive consumption sodium food beverage 48hrs duration study . Subject willing shower use soap/cleansers duration study . Subject willing follow study restriction . Subject past current medical condition might significantly affect pharmacodynamic response topical corticosteroid . Subject clinically significant hypertension circulatory disease . Subject take medication regular basis could modulate blood flow ( constrictor dilator ) , exception prescribe birth control method hormone replacement therapy . Examples drug include nitroglycerin , antihypertensive , antihistamine , NSAIDs , aspirin , phenylpropanolamine , phentolamine . Subject planning use exclusionary overthecounter ( OTC ) medication within 48 hour prior throughout study could modulate blood . Subject history sensitivity/allergy ingredient find test formulation history adverse reaction topical systemic corticosteroid . Subject significant history allergy soap , lotion , emollient , cream , ointment , cosmetic , adhesive , latex . Subject history significant skin condition disorder , example , psoriasis , atopic dermatitis , actinic keratosis , etc . Subject obvious difference In skin color arm presence skin condition , scar tissue , tattoo coloration would interfere placement test site , assessment could compromise safety subject . Subject use topical medication ventral forearm within 1 month prior dose . Subject use tobacco product within 14 day study conduct . Subject clinically significant history drug abuse alcoholism . Subject donate received blood within 30 day prior dose . Subject 's caffeine intake great 500 mg per day ( 1 cup coffee contain approximately 85 mg caffeine ) . Subject plan consumption alcohol , consumption caffeine within 48 hour study conduct throughout entire dose evaluation period study . ( Females ) : Subject pregnant lactating . Subject participate another investigational drug , medical device , biologics study within 30 day prior dose . form female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Vasoconstriction</keyword>
	<keyword>Halobetasol</keyword>
	<keyword>Healthy adult subject</keyword>
</DOC>